Vectura Group plc, (Vectura) along with its subsidiaries, is principally engaged in the research and development of therapeutic products and drug delivery systems for human use. The Company is focused on the development of inhaled pharmaceuticals. It has eight marketed products and a portfolio of drugs in clinical and pre-clinical development, some of which have been licensed to pharmaceutical companies. Vectura also offers its formulation and inhalation technologies to other pharmaceutical companies on a licensing basis. It has development collaborations with a range of pharmaceutical companies, including Boehringer Ingelheim, Novartis and Chiesi. On January 18, 2007, Vectura acquired Innovata plc and its subsidiaries.
25/05/12
Awards under share incentive plan17/05/12
Positive NVA237 Phase III data in COPD Patients03/05/12
Board appointment01/05/12
Total Voting Rights26/04/12
Final Results24/04/12
QVA149 Phase III COPD study meets primary endpoint11/04/12
Notice of Results02/04/12
QVA149 Phase III Data02/04/12
Total Voting Rights01/03/12
Total Voting Rights06/08/10
Vectura Group rallies after signing licensing deal with GlaxoSmithKline22/10/09
Vectura and Novartis Update Investors on lung disease Phase III trials13/08/09
Vectura receives US$6m milestone payment for asthma/COPD product VR31502/03/09
Vectura Group seen lifted by label broadening in US for AstraZeneca’s Symbicort - FinnCap
Copyright © Proactiveinvestors.co.uk, 2012. All Rights Reserved Design & Development: Tehnicom Computers
